Kao, Jia-Horng http://orcid.org/0000-0002-2442-7952
Jeng, Wen-Juei
Ning, Qin
Su, Tung-Hung
Tseng, Tai-Chung
Ueno, Yoshiyuki
Yuen, Man-Fung
Article History
Received: 31 January 2021
Accepted: 21 June 2021
First Online: 23 July 2021
Declarations
:
: JHK: serves as advisor/consultant for AbbVie, Fujirebio Incorporation, Gilead Sciences, GlaxoSmithKline, Janssen, and Sysmex. MFY: serves as advisor/consultant for AbbVie, Aligos therapeutics, Arbutus Biopharma, Bristol Myer Squibb, Dicerna Pharmaceuticals, Finch Therapeutics, GlaxoSmithKline, Gilead Sciences, Janssen, Merck Sharp and Dohme, Clear B Therapeutics, Springbank Pharmaceuticals, Roche and receives grant/ research supports from Assembly Biosciences, Arrowhead Pharmaceuticals, Bristol Myer Squibb, Fujirebio Incorporation, Gilead Sciences, Merck Sharp and Dohme, Springbank Pharmaceuticals, Sysmex Corporation, Roche. Others: Nothing to disclose regarding this submission.